HIPK1-AS1: A Potential Drug Target and Biomarker (G101928846)

Target Name: HIPK1-AS1

NCBI ID: G101928846

HIPK1-AS1

Other Name(s): HIPK1 antisense RNA 1 | HIPK1 antisense RNA 1, transcript variant 1

HIPK1-AS1: A Potential Drug Target and Biomarker

HIPK1-AS1, also known as HIPK1-AS1 Antisense RNA 1, is a non-coding RNA molecule that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function make it an attractive target for researchers to investigate and develop new therapeutic approaches.

Structure and Function

HIPK1-AS1 is a small non-coding RNA molecule that is approximately 200 nucleotides in length. It is composed of a double-stranded RNA molecule that is primarily localized to the cytoplasm of cells. The molecule has a characteristic open-loop structure that allows for interactions with various protein partners.

One of the unique features of HIPK1-AS1 is its ability to interact with the protein kinase HIPK1. HIPK1 is a key regulator of cell growth, metabolism, and autophagy, and is involved in the development and progression of various diseases. By interacting with HIPK1, HIPK1-AS1 can modulate its activity and potentially contribute to the pathogenesis of these diseases.

HIPK1-AS1 has also been shown to interact with several other proteins, including heat shock protein 70 (HSP70), heat shock protein 90 (HSP90), and the protein involved in the immune response, known as PDZP2. These interactions may help to regulate the activity of these proteins and contribute to the unique functions of HIPK1-AS1.

Drug Target Potential

HIPK1-AS1's potential as a drug target is due to its involvement in various cellular processes that are associated with the development and progression of diseases. Its interactions with HIPK1 and other proteins have led to the hypothesis that HIPK1-AS1 may be a target for small molecule inhibitors that can modulate its activity.

One approach to targeting HIPK1-AS1 is to use small molecules that can inhibit its interaction with HIPK1. Such compounds have been shown to be effective in treating various diseases, including neurodegenerative disorders and cancer. For example, a small molecule called U012 has been shown to inhibit the activity of HIPK1 and protect against neurodegenerative damage in animal models of Alzheimer's disease.

Another approach to targeting HIPK1-AS1 is to use RNA interference (RNAi) technology to knockdown its expression in specific cells or tissues. This approach has been used to treat various diseases, including cancer and neurodegenerative disorders. For example, RNAi-based therapies have been shown to be effective in treating cancer by inhibiting the production of new cancer cells.

Biomarker Potential

HIPK1-AS1 has also been identified as a potential biomarker for various diseases. Its interaction with HIPK1 and other proteins suggests that it may be involved in the regulation of cellular processes that are important for disease progression. This suggests that HIPK1-AS1 may be a useful biomarker for diseases that are characterized by the over-expression or dysfunction of HIPK1 and its downstream targets.

For example, HIPK1-AS1 has been shown to be involved in the regulation of neurodegenerative disorders, such as Alzheimer's disease. Its interaction with HIPK1 and other proteins suggests that it may be involved in the regulation of the production and degradation of neurotransmitters, which are involved in the development and progression of these disorders.

Conclusion

HIPK1-AS1 is a non-coding RNA molecule that has been identified as a potential drug target or biomarker for various diseases. Its unique structure and function make it an attractive target for researchers to investigate and develop new therapeutic approaches. By inhibiting its interaction with HIPK1 and other proteins, small molecules and RNAi-based therapies have been shown to be effective in treating various diseases, including cancer and neurodegenerative disorders. Further research is needed to fully understand the mechanisms of HIPK1-AS1 and its potential as a drug target

Protein Name: HIPK1 Antisense RNA 1

The "HIPK1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HIPK1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets